secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001193125-25-004547
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx prices 17.1M-share public offering at $3.50/sh for ~$56.9M net proceeds
------------------------------------------------------------------------------

- Offering of 17,142,857 common shares at $3.50 per share, with 30-day option for up to 2,571,428 additional shares.
- Net proceeds expected to be ~$56.9 million ($65.5 million if over-allotment exercised in full).
- Closing expected January 13, 2025; proceeds to fund commercialization prep, pipeline, working capital.
- Underwriting agreement includes customary representations, warranties, and market standoff provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312525004547/0001193125-25-004547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312525004547/d917502d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer